Fluosol DA and oxygen as an adjuvant to the radiotherapeutic management of advanced head/neck carcinoma.
Lustig
R A
RA
Cooper Hospital/University Medical Center, Robert Wood Johnson Medical School, Camden, NJ 08103.
Rose
C M
CM
McIntosh-Lowe
N L
NL
D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy*; D056486:Chemical and Drug Induced Liver Injury; D003131:Combined Modality Therapy; D004338:Drug Combinations / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005466:Fluorocarbons / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives; D010100:Oxygen / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*
D004338:Drug Combinations; D005466:Fluorocarbons; D006895:Hydroxyethyl Starch Derivatives; C017323:glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D010100:Oxygen